Treatment outcome by risk group after radical prostatectomy in Japanese men

International Journal of Urology

Volumn 8, Issue 6, 2001, Pages 295-300

  Egawa, Shin ^a   Suyama, Kazuho ^a   Arai, Yoichi ^b   Tsukayama, Chohtatsu ^b   Matsumoto, Kazumasa ^a   Kuwao, Sadahito ^a   Baba, Shiro ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

Author keywords

Prostate cancer; Prostate specific antigen failure; Radical prostatectomy; Risk group stratification; Transrectal ultrasound guided prostatic biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER STAGING; FOLLOW UP; HIGH RISK POPULATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; PATIENT COUNSELING; PELVIS LYMPH NODE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOPSY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0034845926     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2001.00301.x     Document Type: Article

References (15)

1. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
2. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
3. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
4. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer
5. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer
6. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer
7. Improved predictability of extracapsular extension and seminal vesicle involvement based on clinical and biopsy findings in prostate cancer in Japanese men
8. Preoperative serum prostate-specific antigen, clinical stage and Gleason sum as basis for predicting final pathological stage in Japanese patients with prostate cancer
9. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
10. Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan
11. Infrequent involvement of the anterior base in low-risk patients with clinically localized prostate cancer and its possible significance in definitive radiation therapy
12. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer
13. Defining the implant treatment volume for patients with low risk prostate cancer: Does the anterior base need to be treated?
14. Natural history of progression after PSA elevation following radical prostatectomy